Laurus Labs Founder and CEO on India's Pharma Sector

The transcript discusses a company's growth in the antiretroviral, oncology, cardiovascular, and diabetes sectors, highlighting its significant market share and investment plans. It addresses supply chain challenges due to regional tensions and outlines strategies for growth, focusing on APIs, CDMO, and fermentation capacity. The company prefers organic growth over acquisitions and aims to sustain profitability. It also explores potential roles in future COVID treatments, despite not being involved in MRNA vaccines.

How does the company ensure cost effectiveness and regulatory compliance?

What strategies is the company implementing to meet the demand for recombinant food proteins?

What opportunities does the company see in the context of mRNA vaccines?